Abstract: A randomized, two-way, crossover study was conducted in 18 fasting, healthy, algerian volunteers to compare the bioavailability of two brands of Omeprazole 20 mg Gastro-Resistant Capsules where MOPRAL (Astra Zeneca) was the reference product. The study was performed at the bioequivalence center of the national control laboratory for pharmaceuticals product. The drug was administered on two treatment days separated by one week washout period. After dosing, serial blood samples were collected for a period of 12 h. A reliable and robust LC-MS/MS (liquid chromatography-tandem mass spectrometry) method has been developed and validated for the estimation of Omeprazole in human plasma. The assay was found to be linear over the range of 5-1,000 ng/mL. The pharmacokinetical and statistical analysis was conducted with Kinetica 4.4.1. AUC 0-t , AUC 0-∞ and C max were tested for bioequivalence. No significant difference was found based on ANOVA; 90% confidence interval ([97.14%-117..85%] for AUC 0-t , [97.17%-117.67%] for AUC 0-∞ ) of test/reference ratio for these parameters were found within bioequivalence acceptance range of 80%-125%. But for the C max , it was not in this acceptance range [73.5%-100.54%]. The results of PK analysis suggested that the reference and test formulations of Omeprazole 20 mg Gastro-Resistant Capsules were not bioequivalent during fasting state in these healthy Algerian volunteers.
Introduction


Bioequivalence of two formulations of the same drug includes equivalence with respect of the rate and extent of their absorption. The area under concentration time curve (AUC) generally serves as the characteristic of the extent of absorption while the peak concentration (C max ) and the time of its occurrence (T max ), reflect the rate of absorption [1] . In bioequivalence studies, the exposure profile of a test drug product is compared to that of a reference drug product [2] .
Omeprazole ( Fig. 1) belongs to a class of antisecretory compounds, the substituted benzimidazoles that suppress gastric acid secretion by specific inhibition of the H + /K + ATPase enzyme system at the secretory surface of the gastric parietal
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cell. This effect is dose-related and leads to inhibition of both basal and stimulated acid secretion irrespective of the stimulus [3] . Omeprazole is a very well tolerated drug, widely used in doses of 20 mg up to 80 mg in duodenal and gastric ulcers, reflux oesophagitis and in the Zollinger-Ellison Syndrome [4] .
As Omeprazole is destroyed in an acid medium, it is administered orally in the form of gastroresistant microgranules into gastroresistant capsules. The absorption of Omeprazole is rapid with a peak plasma obtained approximately in 1 to 2 hours. The absolute bioavailability of an oral dose of Omeprazole is approximately 40%. The volume of distribution of Omeprazole in healthy subjects is approximately 0.3 L/kg body weight. The rate of binding of Omeprazole to plasma proteins is 97%. The majority of its metabolism depends on CYP2C19, which is responsible for the formation of hydroxy-omeprazole.
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The plasma elimination half-life of omeprazole is usually less than one hour after a single oral dose or repeated once daily. Approximately 80% of an oral dose of Omeprazole is excreted in the urine as metabolites, the 20% is excreted in the feces from biliary secretion [3, 5] .
It is reported that the time for appearance of Omeprazole in plasma seemed to be prolonged when given after food intake. The total amount of drug absorbed, however, was not affected [6] . Thus, concomitant food intake does not affect bioavailability [5] .
Because of the low bioavailability and high inter and intra individual variability in the absorption of Omeprazole, it is necessary to perform comparative bioavailability studies [3, 7] . The aim of this study was to evaluate, in healthy Algerian volunteers, the rate and extent of absorption of a local generic Omeprazole formulation against that of the innovator product MOPRAL® from ASTRA ZENECA laboratories in order to evaluate the intra-subject variability of Omeprazole (Coefficient of variation intra-subject:
CVintra of C max and AUCs) and to validate the application of developed LC-MS/MS Omeprazole quantification method. The volunteers were screened by a complete clinical examination and laboratory tests (hematological, biochemical and urinary analysis and serological test) and were requested to be abstained from taking any medication for two weeks before and during the study, from taking vitamins two days prior the study, from taking grapefruit seven days before the study and from smoking, as well as consuming caffeine or drinks or foods containing xanthines related for 48 h prior to the study drug administration.
Materiel and Methods
Study Products
Ethical Consideration
This research was carried according to the Declaration of Helsinki (Seoul, 2008) and GCP (Good Clinical Practice) Guidelines.
The study was conducted at National Control Laboratory for Pharmaceuticals Products (Algiers, Algeria) according to a protocol approved by Research Ethics Committee of University Hospital Center Issad Hassani (Beni Messous, Algiers) and by Ministry of Health.
All the subjects are provided written information consent before entering the study.
Study Design
The study was based on a randomized, single dose, two-way crossover design under fasting condition with a washout period of one week.
In the morning of phases I and II, after an overnight fast (10 h) volunteers were given a single dose of either formulation (reference or test) of Omeprazole 20 mg with 240 mL of water. No food was allowed until 4 h after dose administration, lunch, snack and dinner were given to all volunteers according to a time schedule. The volunteers were continuously monitored by a medical staff throughout the confinement period of the 
Blood Sampling
Approximately, 5 mL of blood samples for Omeprazole assay was obtained through a heparin-locked catheter before (0 h) and at 15', 30', 45', 60', 75', 90', 105', 120', 135', 150', 165', 180', 210', 240', 5 h, 6 h, 7 h, 8 h, 10 h and 12 h after dosing. The blood samples were collected in tubes containing heparin, and centrifuged at 1,800 rpm for 10 min at 20 °C; plasma was separated and kept frozen at -80 °C in properly labeled tubes. After a period of 7 days, the study was repeated in the same manner to complete the crossover design.
Optimization of MS Parameters and Chromatographic Conditions
An LC-MS/MS method was developed and validated, for Omeprazole analysis in plasma samples. All solvents were of HPLC grade, other chemicals and reagents were of analytical grade. Omeprazole and Sildenafil (internal standard Fig. 1 Chromatographic separation was performed using SUPELCO C18 (150 × 4.6) mm, 5 µm, 100 Ǻ column at 40 °C. The mobile phase consisted of methanol of grade HPLC. The mobile phase was eluted at a flow rate of 1.2 mL/min in isocratic mode, each analysis required 5 min. The retention time was 1.6 min for both Omeprazole and Sildenafil. Quantitation was achieved by measurement of the peak area ratio of the drug to the internal standard, using Analyst 1.5.1 software.
The method was validated by following international guideline [12] . The calibration curves were validated over the concentration range of 5-1,000 ng/mL for Omeprazole in human plasma in the low limit of quantification LLOQ of 5 ng/mL.
Sample Preparation
A 50 μL internal standard (Sildenafil, 50 μg/mL) was added to 200 μL plasma sample and vortexed for 30 seconds, then 600 μL of acétonitrile was added and vortexed for 30 seconds and then centrifuged for 10 min at 4,000 g. A 100 μL of the supernatant was transferred to a vial and was added 900 μL of methanol and vortexed for another 30 seconds. Then 20 μL of each sample was injected into the LC-MS/MS for analysis [13] . The procedure described here was applied not only to subject's samples, but also to the extraction of samples for calibration curve and QC (quality control) process.
Pharmacokinetic Analysis
Pharmacokinetic analysis was performed by a model independent method using a Kinetica 4.4.1 computer program [14] . The elimination rate constant (lZ) was obtained as the slope of the linear regression of the log-transformed concentration values versus time data in the terminal phase. The elimination half-life (T 1/2 ) was calculated as 0.693 /lZ. The area under the curve to the last measurable concentration AUC0-t was calculated by the linear trapezoidal rule. The area under the curve extrapolated to infinity AUC0-∞ was calculated as AUC0-t+C t /lZ, where C t is the last measurable concentration.
Statistical Analysis
For the purpose of bioequivalence analysis AUC0-t, AUC0-∞ and C max were considered as primary variables. The bioequivalence of the two products was assessed by means of an analysis of variance (ANOVA GLM procedure; Kinetica 4.4.1 Computer program) for crossover design and calculating standard 90% confidence intervals of the ratio T/R (test/reference) using log-transformed data. The products were considered bioequivalent if the difference between the two compared parameters was found statistically insignificant (p ≥ 0.05) and 90% confidence intervals for these parameters fell within 80%-25% [1, 2, 15].
Results and Discussion
All 18 participants successfully completed both phases of the study with no protocol violations. No serious adverse drug reactions or side effects were reported by the participants or observed by investigators during the study periods.
The relationship between concentration and peak area ratio was found to be linear within the range of 5-1,000 ng/mL with LLOQ of 5 ng/mL. As shown in Table 1 , the intraday accuracy of the method ranged from 91.37% to 103.08% while the intraday precision ranged from 2.24% to 10.47%. The inter-day accuracy ranged from 96.8 % to 102.13 % while the inter-day precision ranged from 2.57 % to 14.29 %. This reproductibility of Omeprazole was able to increase assay sensitivity. Therefore, simple protein precipitation procedure using methanol and acetonitrile has been successfully applied to the extraction of Omeprazole from human plasma. The developed method using the centrifugation technique offers the advantages of a simple and a safe sample preparation procedure without the matrix effect and high throughput with uniformity of extraction which is a critical challenge in LC-MS/MS method development. LLOQ=lower limit of quantification. CV=coefficient of variation = (SD/mean)*100. All the data were presented as arithmetic means.
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Stability studies showed that Omeprazole was stable in plasma for 30 days when stored at -80 °C. The method had a total analysis time of 5 min, which is favored to analyze the samples on a large scale.
Both formulations were rapidly absorbed from the gastrointestinal tract. The peak concentration of 412.44 ng/mL and 366.94 ng/mL for Omeprazole was attained at 2.04 h and 2.02 h after administration of reference and test products respectively, and then declined and remained detectable up until 12 h. The half life elimination was 1.00 h and 1.02 h for reference and test products respectively. These values agree with the bibliographic data [3, 5] . Table 2 shows the pharmacokinetic parameters of Omeprazole for the two brands.
The relative bioavailability of Omeprazole test was 106.999% for AUC0-t, 106.931% for AUC0-∞, and 86.114% for C max .
The 90% confidence limits for AUC0-t, AUC0-∞, and C max as well as the results of the Schuirmann's two one-sided t-tests are also shown in Table 3 .
Mean drug plasma concentration-time profiles of Omeprazole (Fig. 2) were nearly identical, suggesting an equal in vivo performance of the two products.
Ratio AUC0-t/AUC0-∞ of the two formulations was > 80%, suggesting that the duration of sample collection was appropriate, covering > 80% of the complete drug profile. The mea AUC0-∞ an significantly generated by produced by
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Conclusion
n this study This pilot study led to evaluate the variability of Omeprazole. Therefore, it is necessary to do a pivot study with an adequate sample size to overcome the intra-subject variability.
In conclusion, the pharmacokinetic results of this study confirm earlier findings [4, 7, 16, 20, 21] and emphasize that it is advisable in future researches to assess the metabolic status by phenotyping subjects with an adequate test prior to conducting pharmacokinetic studies.
